Novo Nordisk Inc. on Tuesday became the third drug company to say it will slash prices on some of its insulin products. Starting in January 2024, there will be a 75% price cut for NovoLog and NovoLog Mix 70/30, while Novolin and Levemir will see cuts of 65%, the Danish pharmaceutical giant announced in a… read on > read on >



















